Response to Letter to the Editor, ‘Pharmacokinetics partly explains the relationship between CEA level and survival of colorectal cancer patients treated with ramucirumab,’ by Ibrahim et al.

Leggi l'articolo originale


In recent correspondence to the Editor (‘Pharmacokinetics partly explains the relationship between CEA level and survival of colorectal cancer patients treated with ramucirumab’) [1], Ibrahim et al. commented on our paper, ‘Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial’ [2]. The authors rightly observed that our data showed that low baseline serum levels of carcinoembryonic antigen (CEA) were associated with longer overall (OS) and progression-free survival.

Lascia un commento